EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A Case of Immunotherapy Response to BRAF V600E ‐Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy

Yusuke Okayama, Takaaki Tokito iD, Shizuka Shiraishi, Reiko Takaki, Shingo Tsuneyoshi, Hiroyoshi Yamada, Mamoru Nishiyama, Yoshiko Sueyasu, Tomoaki Hoshino

Cancer Reports · 2026

DOI: 10.1002/cnr2.70533 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Yusuke Okayama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Saiseikai Futsukaichi Hospital, Chikushino, Fukuoka, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma of Lung, Drug Resistance, Neoplasm. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The recommended first‐line therapy for BRAF V600E mutant non‐small cell lung cancer (NSCLC) is a combination of dabrafenib and trametinib. Most patients respond to the initial therapy, but some show resistance in the early stages. Additionally, immune checkpoint inhibitors (ICIs) are often used after resistance develops; however, the benefits of ICIs in patients with BRAF V600E mutant NSCLC remain unclear. Case Presentation We report a case of a 67‐year‐old man who was clinically diagnosed with lung adenocarcinoma cT2aN3M1c (BRA) stage IVB (BRAF V600E mutation‐positive, programmed death‐ligand 1; 90%). The patient developed early resistance to the combination of dabrafenib and trametinib but responded well to ICI.

Conclusion

This case suggests that ICI may provide durable clinical benefit even after early resistance to BRAF/MEK inhibition in selected patients with high PD‐L1 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAdenocarcinoma of LungDrug Resistance, NeoplasmImmune Checkpoint InhibitorsHumansMaleAgedPyrimidinonesProto-Oncogene Proteins B-rafPyridonesOximesImidazolesMutation

Stichwörter der Autor:innen

BRAF V600EPD‐L1dabrafenibimmune checkpoint inhibitortrametinib

Substanzen

trametinibdabrafenibPyrimidinonesProto-Oncogene Proteins B-rafPyridonesOximesImidazolesBRAF protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Saiseikai Futsukaichi Hospital, Chikushino, Fukuoka, Japan.
  • Division of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Kurume, Fukuoka, Japan.

ORCID-Profile: Takaaki Tokito

Zitieren

APA

Okayama, Y., Tokito, T., Shiraishi, S., Takaki, R., Tsuneyoshi, S., Yamada, H., Nishiyama, M., Sueyasu, Y., & Hoshino, T. (2026). A Case of Immunotherapy Response to BRAF V600E ‐Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy. Cancer Reports. https://doi.org/10.1002/cnr2.70533

Vancouver

Okayama Y, Tokito T, Shiraishi S, Takaki R, Tsuneyoshi S, Yamada H, et al. A Case of Immunotherapy Response to BRAF V600E ‐Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy. Cancer Reports. 2026. doi:10.1002/cnr2.70533

BibTeX
@article{Okayama2026,
  author = {Okayama, Yusuke and Tokito, Takaaki and Shiraishi, Shizuka and Takaki, Reiko and Tsuneyoshi, Shingo and Yamada, Hiroyoshi and Nishiyama, Mamoru and Sueyasu, Yoshiko and Hoshino, Tomoaki},
  title = {A Case of Immunotherapy Response to BRAF V600E ‐Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70533}
}
Kostenlos starten →